Omonike Olaleye to Male
This is a "connection" page, showing publications Omonike Olaleye has written about Male.
Connection Strength
0.073
-
Fernandes P, Wang K, Timmerman J, Reyes A, Holmes F, Olaleye OA, Salihu HM, Moerchen VA, Belcher HME, Copeland-Linder N, Noble CA, Vamos CA, Armstrong A, Waters CR, Long-White D, Brown C, Reddy MM, Kuo A. Success of Maternal and Child Health Pipeline Training Programs: Alumni Survey Results. Matern Child Health J. 2022 Aug; 26(Suppl 1):69-77.
Score: 0.015
-
Fernandes P, Wang K, Timmerman J, Reyes A, Holmes F, Olaleye OA, Salihu HM, Moerchen VA, Belcher HME, Copeland-Linder N, Noble CA, Vamos CA, Armstrong A, Waters CR, Long-White D, Brown C, Reddy MM, Kuo A. Success of Maternal and Child Health Pipeline Training Programs: Alumni Survey Results. Matern Child Health J. 2022 Jul; 26(7):1415-1423.
Score: 0.014
-
Ekpenyong O, Gao X, Ma J, Cooper C, Nguyen L, Olaleye OA, Liang D, Xie H. Pre-Clinical Pharmacokinetics, Tissue Distribution and Physicochemical Studies of CLBQ14, a Novel Methionine Aminopeptidase Inhibitor for the Treatment of Infectious Diseases. Drug Des Devel Ther. 2020; 14:1263-1277.
Score: 0.013
-
Salihu HM, Henshaw C, Salemi JL, Dongarwar D, Wudil UJ, Olaleye O, Godbole N, Aggarwal A, Aliyu MH. Temporal trends and black-white disparity in mortality among hospitalized persons living with HIV in the United States. Medicine (Baltimore). 2019 Mar; 98(9):e14584.
Score: 0.012
-
Ekpenyong O, Cooper C, Ma J, Liang D, Olaleye O, Xie H. A simple, sensitive and reliable LC-MS/MS method for the determination of 7-bromo-5-chloroquinolin-8-ol (CLBQ14), a potent and selective inhibitor of methionine aminopeptidases: Application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Oct 15; 1097-1098:35-43.
Score: 0.011
-
Vijayakumar S, Finney John S, Nusbaum RJ, Ferguson MR, Cirillo JD, Olaleye O, Endsley JJ. In vitro model of mycobacteria and HIV-1 co-infection for drug discovery. Tuberculosis (Edinb). 2013 Dec; 93 Suppl:S66-70.
Score: 0.008